<DOC>
	<DOCNO>NCT02559895</DOCNO>
	<brief_summary>The purpose study assess ALD403 prevention migraine headache frequent episodic migraineurs .</brief_summary>
	<brief_title>A Multicenter Assessment ALD403 Frequent Episodic Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Diagnosis migraine ≤ 50 year age ( ICHDII , 2004 Section 1 ) History migraine ≥ 12 month ≤ 14 headache day least 4 migraine day ( migraine day count headache day ) 28 day period 3 month prior screen During 28 day follow screen visit , subject experience ≤ 14 headache day least 4 migraine day ( migraine day count headache day ) record eDiary No use botulinum toxin migraine medical/cosmetic reason require injection head , face , neck 4 month prior screen 28 day period prior randomization Headache eDiary complete least 25 28 day prior randomization Confounding pain syndrome , e.g . fibromyalgia , complex regional pain syndrome pain syndrome require regular analgesia Psychiatric condition uncontrolled untreated , include condition control minimum 6 month prior screen History diagnosis complicate migraine ( ICHD II , 2004 Section 1 ) , chronic tensiontype headache , hypnic headache , cluster headache , hemicrania continuum , new daily persistent headache , migraine brainstem aura , sporadic familial hemiplegic migraine Unable differentiate migraine headache Have clinically significant concurrent medical condition Receipt monoclonal antibody treatment within 6 month screen ( within outside clinical trial ) Previously dose ALD403 monoclonal antibody target CGRP pathway</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>